Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The two major classes of antidiabetic drugs, sulfonylureas and metformin, may differentially affect macrovascular complications and mortality in diabetic patients. We compared the long-term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic patients who had a history of coronary artery disease (CAD). RESEARCH DESIGN AND METHODS: This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total of 304 type 2 diabetic patients with CAD, mean age = 63.3 years (range, 36–80 years), were enrolled. Participants were randomly assigned to receive either glipizide (30 mg daily) or metformin (1.5 g daily) for 3 years. The primary end points were times to the composite of recurrent cardiovascular events, including death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke, or arterial revascularization. RESULTS: At the end of study drug administration, both groups achieved a significant decrease in the level of glycated hemoglobin (7.1% in the glipizide group and 7.0% in the metformin group). At a median follow-up of 5.0 years, 91 participants had developed 103 primary end points. Intention-to-treat analysis showed an adjusted hazard ratio (HR) of 0.54 (95% CI 0.30–0.90; P = 0.026) for the composites of cardiovascular events among the patients that received metformin, compared with glipizide. The secondary end points and adverse events were not significantly different between the two groups. CONCLUSIONS: Treatment with metformin for 3 years substantially reduced major cardiovascular events in a median follow-up of 5.0 years compared with glipizide. Our results indicated a potential benefit of metformin therapy on cardiovascular outcomes in high-risk patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Follow-up studies involving metformin appeared to support a potential cardiovascular benefit, but these studies were small and the findings were not robust.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [207]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Cited by
Items 301–366 of 366
Metformin in the Era of New Antidiabetics
Al-Mahdi, E. A. R., Barrios, V., & Zamorano, J. L. (2021) · Future Cardiology · doi:10.2217/fca-2020-0195 · Cited by 2
FULMINANT MYOCARDITIS-A UNIQUE COMPLICATION OF COVID-19
Ahmed, A., Young, S. K., & Lantz, R. H. (2021) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(21)03378-7 · Cited by 2
Rosiglitazone, medical reversal, and back to basics for diabetes.
Prasad, V. K. (2014) · PubMed · Cited by 2
Sarah, E. H., Omri, N. E., Ibrahimi, A., & Jaoudi, R. E. (2020) · Gene Reports · doi:10.1016/j.genrep.2020.100787 · Cited by 2
Guía latinoamericana de recomendaciones al egreso de un síndrome coronario agudo
Ponte-Negretti, C. I., Zaidel, E. J., López-Santi, R., Múnera, A. G., Bryce, A., M, S. N., Espinoza, J., Gaibor, J. C., Valcárcel, Y., Antonio, C. D., et al. (2024) · Archivos de cardiología de México · doi:10.24875/acm.m24000096 · Cited by 6
Hao, X., Cui, J., Zhang, M., & Zhang, D. (2025) · American Journal of Translational Research · doi:10.62347/ynwl3428 · Cited by 2
Is diabetes still a state of premature cardiovascular death?
Fisher, M. (2016) · Practical Diabetes · doi:10.1002/pdi.2057 · Cited by 1
Kim, S. S., & Kim, I. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_9 · Cited by 1
Li, K., Liu, P., Ye, J., Liu, M., & Zhu, L. (2024) · Aging · doi:10.18632/aging.205775 · Cited by 4
Personalized epigenetics of aging
Maugeri, A., Barchitta, M., Favara, G., Lio, R. M. S., & Agodi, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23802-4.00016-8 · Cited by 1
Novel Drug Targets in Diastolic Heart Disease
Er, T., Martinac, B., & Hool, L. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168055 · Cited by 1
“In clinical trials, metformin treatment reduces mortality by reducing cardiovascular risk [183–185].”
Sulfonylurea treatment in type 2 diabetes.
Bester, K., Ton, J., & Korownyk, C. S. (2018) · Europe PMC (PubMed Central) · Cited by 1
Recent Perspective of Metformin
Hong, S. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.2.85 · Cited by 1
“메트포 민과 설포닐유레아계 약제인 글리피자이드의 장기적인 심혈관 질환 발생에 대한 영향을 비교한 연구도 있었다[15].”
USO DA METFORMINA COM ÊNFASE EM PACIENTES CARDÍACOS
Filho, P. F. P., da Silva, K. G., Passos, A. C., de Souza, A. B. C., Mota, M. L. B. R., & de Sousa, M. N. A. (2021) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · doi:10.5281/zenodo.5161770 · Cited by 1
Mechanisms under Metformin and Rapamycin as Anti-aging DrugsPreprint
Feng, Q., Chen, B., Wang, C., Nie, C., & Li, T. (2020) · Authorea · doi:10.22541/au.159372989.91282630 · Cited by 1
Lehrke, M. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0071-z
„Highlights“ des Diabetes Update 2013: Wichtige Studienergebnisse für den Diabetologen
Scherbaum, W. A. (2013) · Der Diabetologe · doi:10.1007/s11428-012-0977-z
Kirkland, J. L., & Tchkonia, T. (2015) · Springer eBooks · doi:10.1007/978-3-319-23246-1_19
Metformin vs. Glipizide for Patients with Diabetes and Coronary Disease
Brett, A. S. (2013) · Journal watch · doi:10.1056/nejm-jw.na31389
Wie kriegt man das Gefäßrisiko in den Griff?
Stirban, O. A., & Tschöpe, D. (2015) · Info Diabetologie · doi:10.1007/s15034-015-0499-z
“Im Gegenteil, in den letzten Jahren haben sich die bereits 1988 von der UKPD-Studie erbrachten Hinweise erhärtet, dass Metformin das KVRisiko reduziert [35, 36].”
BackgroundUsage of metformin in patients with type 2 diabetes mellitus
Huang, W. (2016) · UTAS Research Repository · doi:10.25959/23240615
Connell, J. L. O. (2017) · MOJ Gerontology & Geriatrics · doi:10.15406/mojgg.2017.02.00048
“0%) but metformin was associated with a 12% absolute risk reduction in the composite primary outcome of nonfatal MI, nonfatal stroke, revascularization, CV mortality, or all-cause mortality [10].”
BackgroundWhy Metformin Is so Important for Prevention and Therapy in Climacteric Women
Kuliczkowska-Płaksej, J., Milewicz, A., Brona, A., & Bolanowski, M. (2018) · ISGE series · doi:10.1007/978-3-319-63540-8_11
Fisher, M. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch39
Cardiovascular outcome trials in diabetes: what have we learnt?
Kirby, M. G., & Boon, N. (2018) · Trends in Urology & Men s Health · doi:10.1002/tre.642
Ji, L., & Gao, L. (2018) · Scientia Sinica Vitae · doi:10.1360/n052018-00081
Diabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_6-1
Herz und Diabetes: Neues aus 2012
Lehrke, M. (2013) · Der Diabetologe · doi:10.1007/s11428-012-1013-z
Buhse, S., & Mühlhauser, I. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_32
Mohan, M. (2019) · Discovery Research Portal (University of Dundee)
Mesa 3: Efectos cardiovasculares de fármacos antidiabéticos
Ávila, P. J., Milrad, S. A., Forlino, M., Fábregues, S., Vázquez, F., Grosso, C., Schindler, A., Zambon, F., Rodríguez, M. V., Santos, N. C. G., et al. (2020) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v54i2sup.253
“Journal of the American College of Cardiology 2019; 73(15)-1945-1947.”
BackgroundYan, Y., Li, T., Li, Z., He, M., Wang, D., Xu, Y., Yang, X., Bai, Y., Lao, Y., Zhang, Z., et al. (2020) · doi:10.21203/rs.3.rs-109664/v1
Self-citationМеханізми реалізації кардіопротективних ефектів метформіну (огляд літератури)
Олещук, О. М., & Лой, Г. Я. (2020) · Pharmacology and Drug Toxicology · doi:10.33250/14.05.299
ABO-OUF, A. M., & ARAFA, M. A. A. (2021) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2021.153947
Characterizing the Effects of Metformin on Brain Development following Cranial Irradiation
Yuen, N. (2020) · TSpace (University of Toronto)
Diabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_6
Diabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_6
Diabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_6-2
Edição Completa, Vol 4, n.09, 2021
(2021) · Revista JRG de Estudos Acadêmicos · doi:10.29327/257411.4.9-1
Effetti pleiotropici della metformina: hanno rilevanza clinica?
Sesti, G. (2022) · il Diabete · doi:10.30682/ildia2202b
Hanif, M. A., Saeed, A., Khan, S., Zainab, S., Khokhar, A., & Shuaib, M. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs221651479
Metformin and type 2 diabetes in the era of cardiovascular outcome trials; A narrative review
Kitsios, K., Trakatelli, C., Sarigianni, M., Kyriazidou, Α., Aroutsidis, F., Mastrogiannis, Κ., & Kotsis, V. (2022) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1035
Secondary Diseases of the Kidney
Natale, P., Wong, M. G., Strippoli, G. F., Tunnicliffe, D. J., Cooper, T. E., & Pollock, C. A. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch24
Control of Blood Glucose and Cardiovascular Risk Profile
Ciardullo, S., & Perseghin, G. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_28
Eriş, D. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2576
Mühlhauser, I., Buhse, S., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_34
Time to revisit the true role of metformin in type 2 diabetes mellitus
López‐Candales, A., Monte, S. V., Sawalha, K., & Norgard, N. B. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2023.2224036
“Second, not only metformin was shown to be better than first- and second-generation sulfonylureas with regard to CVD outcomes [40,41] but also, the combined use of the thiazolidinedione, pioglitazone, with metformin showed significant slowing of atherosclerotic injury [42].”
BackgroundChronic Kidney Disease and Cardiovascular Outcomes
Colbert, G. B., Gaur, L., Elrggal, M. E., Madariaga, H. M., & Lerma, E. V. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_16
Personalized epigenetic management of diabetes
Sapehia, D., Bhardwaj, N., Goyal, H., Mahajan, A., Singh, P., & Kaur, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23802-4.00017-x · Cited by 1
Qi, J., Dong, M., Gou, Q., & Zhu, H. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01269-x
Hussain, I., MacLeod, J., Dunn, F., Bickel, P. E., Abreu, M., McNulty, N., Lingvay, I., Kermani, A., & Abreu, M. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch03
Low Hepatic CEACAM1 Tethers Metabolic Dysfunction Steatohepatitis to Atherosclerosis
Khoury, S. E., Harake, S. N. A., Youssef, T., Risk, C. E., Helou, N., Doumet, N. M., Aramouni, K., Azar, S. T., Najjar, S. M., & Ghadieh, H. E. (2025) · Livers · doi:10.3390/livers5030034 · Cited by 1
“It was also shown that metformin therapy for 3 years reduces major cardiovascular complications significantly in patients with T2D [247].”
Abdelgadir, O., Njoroge, S. W., Babu, A. S., Tahashilder, M. I., Hernández‐Pérez, J. G., Torres‐Sánchez, L., Hussain, M. R., Tezanos, A. G. V., Malagaris, I., Khalife, W. I., et al. (2025) · Annals of Epidemiology · doi:10.1016/j.annepidem.2025.12.004
Metformin alleviates diastolic dysfunction in mice with experimental diabetic cardiomyopathy
Chan, J. S. F., Dakhili, S. A. T., Wu, N. R., Stenlund, M. J., King, A. N., Dong, L., Mangra-Bala, I. A., Shafaati, T., Ferrari, S. R., Greenwell, A. A., et al. (2025) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2025.100825 · Cited by 3
“…and Effect of Antidiabetic Drugs on Type 2 Diabetes Mellitus with Coronary Artery Disease (SPREAD-DIMCAD) demonstrated that metformin treatment is associated with a reduction for risk of myocardial infarction and major adverse cardiovascular events when compared to conventional therapy [17,18].”
Huang, R., Dalton, J., Eichbaum, Y. K., Heard, J. C., Ezeonu, T., Fras, S. I., Garcia, A. G., Oris, R. J., Baidya, J., Narayanan, R., et al. (2025) · Spine · doi:10.1097/brs.0000000000005586
Volke, V., Katus, U., Johannson, A., Toompere, K., Heinla, K., Rünkorg, K., & Uusküla, A. (2022) · Figshare · doi:10.6084/m9.figshare.21366056
Volke, V., Katus, U., Johannson, A., Toompere, K., Heinla, K., Rünkorg, K., & Uusküla, A. (2022) · Figshare · doi:10.6084/m9.figshare.21366059
Volke, V., Katus, U., Johannson, A., Toompere, K., Heinla, K., Rünkorg, K., & Uusküla, A. (2022) · Figshare · doi:10.6084/m9.figshare.21366062
Alharran, A. M., Alsaid, M. A., Hussain, A. A., Aladwani, F. A., & Alaradi, H. (2026) · Arab Journal of Urology · doi:10.1080/20905998.2026.2637371
“Metformin, a widely known antidiabetic agent, has been reported to improve survival for patients with diabetes or impaired fasting glucose while controlling hyperglycemia, weight gain, and macrovascular adverse events [14,15].”
Dimnjaković, J., Buble, T., & Brborović, O. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1760695
“A randomized study showed that sulfonylurea in comparison to metformin caused more CV events without death outcome and death of any outcome (73).”
Mohammadi, D., Sadeghirad, B., Rasouli, M. A., Saed, L., Baradaran, H. R., & Moradi, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02226-9
Pharmacological interventions of metabolic therapies
Ruan, C., & Hua, Y.-J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34186-1.00003-7
Ahmed, S., McCollin, S. P., Martí-Carvajal, A. J., Akus, M., Baron, D. W., Razzaq, S. A., Scudder, P. N., Honigsberg, E. J., Nasir, S., Peng, K., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016380
Cardioprotective Effect of Metformin Treatment in Mouse Model of Experimental Autoimmune Myocarditis
Czepiec, M., Fryt, K., Jaźwa, A., Laimbacher, A., Kania, G., Siedlar, M., Tyszka‐Czochara, M., & Błyszczuk, P. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/6615227
Metadata
- Authors
- Hong, J., Zhang, Y., Lai, S., Lv, A., Su, Q., Dong, Y., Zhou, Z., Tang, W., Zhao, J., Cui, L., Zou, D., Wang, D., Li, H., Liu, C., Wu, G., Shen, J., Zhu, D., Wang, W., Shen, W., Ning, G., & on behalf of the SPREAD-DIMCAD Investigators
- Affiliations
- Shanghai Jiao Tong University (CN)
- Johns Hopkins University (US)
- Second Xiangya Hospital of Central South University (CN)
- Shandong University (CN)
- Second Military Medical University (CN)
- The First Affiliated Hospital of Wenzhou Medical College, Zhejiang Province, China
- Sir Run Run Shaw Hospital (CN)
- Jiangsu Province Hospital (CN)
- Shanghai Ten’s People’s Hospital of Tongji University, Shanghai, China
- Nanfang Hospital (CN)
- Nanjing Drum Tower Hospital (CN)
- Corresponding author
- Ning, Guang
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-04-13
- Volume
- 36
- Issue
- 5
- Pages
- 1304-1311
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3631843
- OpenAlex
- W2141199290
- Cited by
- 366
- References
- 37
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 20 · 2023: 26 · 2022: 43 · 2021: 35 · 2020: 44 · 2019: 31 · 2018: 31 · 2017: 28 · 2016: 30 · 2015: 20 · 2014: 22 · 2013: 12
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81170784, 1994DP131044, 201002002, 2012ZX09303006-001, 30971077)
- Shanghai Municipal Education Commission
- National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology (2012ZX09303006‐001)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- metformin, glipizide, type 2 diabetes, coronary artery disease, cardiovascular outcomes, sulfonylureas, myocardial infarction, stroke, cardiovascular mortality, HbA1c, macrovascular complications
- MeSH terms
- Adult, Aged, Aged, 80 and over, Coronary Artery Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glipizide, Humans, Male, Metformin, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.